Cure8 research brief
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting biologics.
Adult IBD patients considering anti‑TNF therapy, clinicians who prescribe biologics, researchers studying predictive biomarkers, and teams managing biologic-naïve patients.
This prospective cohort enrolled 100 biologic‑naïve IBD adults (50 Crohn’s disease, 50 ulcerative colitis) treated with induction adalimumab or infliximab and followed to week 24. Baseline LRG was higher in IBD patients than controls.
The authors report that baseline serum LRG > 29 µg/mL was associated with primary non‑response, with moderate sensitivity and specificity and high negative predictive values in both UC and CD. The finding is presented as an adjunctive biomarker for pre‑treatment risk estimation rather than a definitive test.
This report is based on a single prospective cohort from an Egyptian population and uses clinical, biochemical, and endoscopic outcomes at 24 weeks.
Single‑cohort study from Egypt with 24‑week follow-up; findings are promising but need validation in broader populations before routine clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
